Delving into the Latest Updates on H3 receptor antagonists 13g(Johnson & Johnson) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-morpholine

Target

H3 receptor

Mechanism

H3 receptor antagonists(Histamine H3 receptor antagonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Nervous System Diseases

Inactive Indication-

Originator Organization

Johnson & Johnson Pharmaceutical Research & Development LLC

Active Organization

Johnson & Johnson Pharmaceutical Research & Development LLC

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC19H30N2O2

InChIKeyAYEMHSJPBSPTSA-UHFFFAOYSA-N

CAS Registry397276-53-8

The synthesized compound, 1-(2-ethoxyethyl)-4-(pent-1-yn-1-yl)piperidin-4-yl propionate (EPPP), and its 1:1 complex with β-cyclodextrin (EPPPβCD) have been characterized for the first time through a comprehensive suite of analytical methods. This study explores the therapeutic potential of EPPPβCD in modulating immune responses and accelerating the resolution of septic inflammation induced by chromium and vanadium ions in outbred male rats. The research highlights the significant impact of EPPPβCD on the dynamics of regulatory T lymphocytes (Tregs), notably causing a reduction in the CD4+CD25+ fractions at the onset of inflammation. This effect is attributed to the inhibition of Treg proliferation, which is crucial in hastening the resolution of inflammation. These findings underscore the potential of EPPPβCD as a promising therapeutic agent in controlling and mitigating inflammation mediated by heavy metal exposure, thereby offering a new avenue for the development of anti-inflammatory treatments.

100 Deals associated with H3 receptor antagonists 13g(Johnson & Johnson)

Login to view more data